Regorafenib

證據等級: L5

預測適應症: 8 個

REGORAFENIB: Repurposing Evaluation — Insufficient Data to Complete Full Assessment

One-Sentence Summary

REGORAFENIB (DrugBank ID: DB08896) is a drug for which the current Evidence Pack contains no approved indication records, no mechanism of action data, and no TxGNN-predicted indications. A complete repurposing evaluation cannot be generated at this time; the report below documents what is available and specifies the remediation steps required before moving forward.

Quick Overview

Item	Content
Original Indication	Not available in current data
Predicted New Indication	No predictions returned
TxGNN Prediction Score	Not available
Evidence Level	Below L5 — no predictions or studies linked
Germany Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No predicted indications were returned by the TxGNN pipeline for this candidate (predicted_indications: []). Without a target indication to evaluate, a mechanistic rationale cannot be constructed.

Additionally, the mechanism of action (MOA) field is flagged as a data gap (DG002, severity: High). Without MOA information, it is not possible to reason about pharmacological plausibility even if a candidate indication were proposed.

What is needed before this section can be written:

Re-run the TxGNN model to confirm whether prediction output was suppressed due to a pipeline error or genuinely returned no candidates above threshold.
Retrieve MOA data from DrugBank (DG002 remediation: query DrugBank API for DB08896).

Clinical Trial Evidence

Currently no related clinical trials registered for the predicted indication — no target indication is available.

Literature Evidence

Currently no related literature available — no target indication is available.

Germany Market Information

REGORAFENIB has 0 authorizations in the current regulatory dataset. No product listings are available to display.

Safety Considerations

Please refer to the package insert for safety information.

Note: Two blocking data gaps prevent safety assessment:

DG001 (Blocking): Package insert warnings and contraindications have not been parsed. Remediation: download the PDF from the official regulatory authority and extract the text.

DG002 (High): MOA data is absent, which prevents DDI mechanistic analysis. Remediation: query the DrugBank API for DB08896.

No drug interaction data was found (DDI query status: not_found, 0 interactions).

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for REGORAFENIB is critically incomplete — there are no predicted indications, no approved indication text, no MOA, and no safety data available for evaluation. Proceeding without these inputs would produce an unreliable assessment.

To proceed, the following is needed:

Diagnose TxGNN pipeline — Confirm whether the empty predicted_indications array reflects a genuine below-threshold result or a pipeline failure (e.g., missing graph embedding for DB08896).
Retrieve MOA from DrugBank API — Query DB08896 to obtain pharmacology, mechanism of action, and drug categories (resolves DG002).
Parse package insert — Download and extract warnings, contraindications, and approved indications from the regulatory authority PDF (resolves DG001).
Re-run Evidence Pack generation — After filling DG001 and DG002, regenerate the Evidence Pack (v5 or later) and resubmit for report generation.
Confirm target indication — Once TxGNN predictions are available, select the top-ranked indication and retrieve linked clinical trials and literature via the evidence pipeline.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.